Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q15147
UPID:
PLCB4_HUMAN
Alternative names:
Phosphoinositide phospholipase C-beta-4; Phospholipase C-beta-4
Alternative UPACC:
Q15147; B7ZLK6; E2QRH8; Q17R56; Q5JYS8; Q5JYS9; Q5JYT0; Q5JYT3; Q5JYT4; Q9BQW5; Q9BQW6; Q9BQW8; Q9UJQ2
Background:
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4, also known as Phospholipase C-beta-4, plays a pivotal role in the production of second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). These molecules are crucial for various cellular processes, including signal transduction in the retina.
Therapeutic significance:
This protein's involvement in Auriculocondylar syndrome 2, a craniofacial malformation syndrome, underscores its potential as a target for therapeutic intervention. Understanding the role of 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 could open doors to potential therapeutic strategies.